2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W017462S
    Creatine-d5 monohydrate 99.93%
    Creatine-d5 (monohydrate) is the deuterium labeled Creatine monohydrate. Creatine monohydrate, an endogenous amino acid derivative, plays an important role in cellular energy, especially in muscle and brain[1].
    Creatine-d5 monohydrate
  • HY-B2068
    Iron sucrose 8047-67-4
    Iron sucrose (Iron saccharate) is a intravenous iron preparation and a pro-oxidant agent. Iron sucrose has the potential for iron deficiency anemia treatment.
    Iron sucrose
  • HY-N2056
    11-​Keto-​beta-​boswellic acid 17019-92-0 99.96%
    11-Keto-beta-boswellic acid (11-Keto-β-boswellic acid) is a pentacyclic triterpenic acid of the oleogum resin from the bark of the Boswellia serrate tree, popularly known as Indian Frankincense. 11-Keto-beta-boswellic acid has the anti-inflammatory activity is primarily due to inhibit 5-lipoxygenase (5-LOX) and subsequent leukotriene and nuclear factor-kappa B (NF-κB) activation and tumor necrosis factor alpha generation production.
    11-​Keto-​beta-​boswellic acid
  • HY-115062
    MJ33 lithium salt 1007476-63-2 ≥99.0%
    MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.
    MJ33 lithium salt
  • HY-W010388S1
    Creatine-d3 143827-19-4 98.95%
    Creatine-d3 is the deuterium labeled Creatine[1]. Creatine, an endogenous amino acid derivative, plays an important role in cellular energy, especially in muscle and brain[2].
    Creatine-d3
  • HY-14877
    Anagliptin 739366-20-2 99.91%
    Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively.
    Anagliptin
  • HY-15497
    AZD7687 1166827-44-6 99.80%
    AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research.
    AZD7687
  • HY-102037
    SSTR5 antagonist 1 1628741-91-2 99.91%
    SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC50s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively.
    SSTR5 antagonist 1
  • HY-109114
    Dersimelagon 1835256-48-8 98.66%
    Dersimelagon (MT-7117) is an orally active, selective melanocortin 1 receptor (MC1R) agonist with EC50 values of 8.16, 3.91, 1.14 and 0.251 nM for human (h), cynomolgus monkey (cm), mouse (m) and rat (r) MC1R, respectively. Dersimelagon shows good affinity for hMC1R and hMC4R with Ki values of 2.26, 32.9 nM, respectively. Dersimelagon can be used for the research of skin pigmentation.
    Dersimelagon
  • HY-121515
    DPM-1001 1471172-27-6
    DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property.
    DPM-1001
  • HY-124754
    Navacaprant 2244614-14-8 99.97%
    Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively. Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy.
    Navacaprant
  • HY-129571
    BioE-1115 1268863-35-9 99.56%
    BioE-1115 is a highly selective and potent PAS kinase (PASK) inhibitor with an IC50 of ~4 nM. BioE-1115 is also a potent casein kinase 2α inhibitor with an IC50 of ~10 μM.
    BioE-1115
  • HY-10171
    NPS-2143 hydrochloride 324523-20-8 99.80%
    NPS-2143 hydrochloride (SB-262470A hydrochloride), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 hydrochloride (SB-262470A hydrochloride) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor.
    NPS-2143 hydrochloride
  • HY-112144
    TP0463518 1558021-37-6 99.25%
    TP0463518 is a potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor with a Ki value of 5.3 nM for human PHD2. TP0463518 also inhibits human PHD1/PHD3 with IC50s of 18 and 63 nM as well as monkey PHD2 with an IC50 value of 22 nM.
    TP0463518
  • HY-U00141
    ABTL-0812 57818-44-7 99.57%
    ABTL-0812 (α-Hydroxylinoleic acid) induces endoplasmic reticulum (ER) stress-mediated autophagy. ABTL-0812 is a first-in-class small molecule with anti-cancer activity.
    ABTL-0812
  • HY-14472
    Tesofensine 195875-84-4 99.35%
    Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
    Tesofensine
  • HY-19383
    Ertiprotafib 251303-04-5 98.86%
    Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
    Ertiprotafib
  • HY-21088
    3-Amino-2-piperidinone 1892-22-4
    3-amino-2-piperidinone is a cyclic ornithine analogue. 3-amino-2-piperidinone can be used to synthesize N-(2-oxopiperidin-3-yl)dodecanamide. N-(2-oxopiperidin-3-yl)dodecanamide inhibits Fas-induced Apoptosis.
    3-Amino-2-piperidinone
  • HY-75958
    Vitamin D4 511-28-4 99.59%
    Vitamin D4 (22-Dihydroergocalciferol) is a Vitamin D derived from fungi. The precursor of Vitamin D4 is 22,23-dihydroergosterol.
    Vitamin D4
  • HY-N0686
    Pseudoprotodioscin 102115-79-7 98.76%
    Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
    Pseudoprotodioscin
Cat. No. Product Name / Synonyms Application Reactivity